THE IMPACT OF FIBROSIS ON THE RISK OF LONG-TERM MORBIDITY AND MORTALITY IN CHRONIC HEPATITIS C PATIENTS TREATED IN THE VETERANS ADMINISTRATION HEALTH CARE SYSTEM
Author(s)
Matsuda T1, McCombs J1, Tonnu-Mihara I2, Saab S3, Hines P4, LItalien GJ5, Kalsekar A6, Yuan Y4
1University of Southern California, Los Angeles, CA, USA, 2VA Long Beach, Long Beach, CA, USA, 3David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 4Bristol-Myers Squibb, Plainsboro, NJ, USA, 5Bristol Myers Squibb, Wallingford, CT, USA, 6Bristol-Myers Squibb, Princeton, NJ, USA
OBJECTIVES: Clinicians need a reliable, non-invasive predictor of future liver-related events with which to monitor disease progress and alert untreated patients to start therapy before treatment effectiveness is compromised. This study documents the impact of FIB-4 > 3.25 [probable fibrosis] on mortality risk and evaluates if treatment effectiveness is compromised if initiated after fibrosis is detected. METHODS: Data from a large sample of U.S. veterans were selected using the Veterans Administration’s HCV clinical registry [CCR] which compiles patients EMR data from 1999 to present. Selection criteria required data on viral genotype and sufficient laboratory data with which to calculate FIB-4 scores. Time to death was analyzed with Cox proportional hazards models using treatment before/after FIB-4 > 3.25, age, genotype, gender, race, diabetes and other patient characteristics as independent risk factors. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PIN21
Topic
Epidemiology & Public Health
Disease
Infectious Disease (non-vaccine)